Urologix, Inc. (ULGX: OTCQB) | Urologix to Host Its Fiscal Year 2015 Third Quarter Conference Call

715

Urologix to Host Its Fiscal Year 2015 Third Quarter Conference Call

May 05, 2015

OTC Disclosure & News Service

MINNEAPOLIS, May 5, 2015 (GLOBE NEWSWIRE) — Urologix, Inc. (OTCQB:ULGX) will host a conference call to present third quarter fiscal year 2015 results on Tuesday, May 12, 2015 at 4:00 p.m. CT, following the Company’s post-market press release on the same day. On the day of the call, please dial 1-877-359-9508 and enter the conference ID 42703418 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.

Webcast listeners should log on at least 10 minutes prior to the scheduled start time of the call to register and download or install any required audio software. A replay of the call will be available until May 19, 2015 at 10:59 p.m. CT. To listen to the replay, please dial 1-855-859-2056 and enter the conference ID 42703418.

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix’s Cooled ThermoTherapy™ system produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Cooled ThermoTherapy product line includes the CoolWave® and Targis® Control Units and the CTC Advance® and Targis catheter families. The Prostiva® RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.

CONTACT: Scott Madson
         Chief Financial Officer
         Urologix, Inc.
         763-475-1400
         investor-relations@urologix.com

Copyright © 2015 GlobeNewswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Source: otc markets

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.